# Adaptyv Biosystems

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adaptyv-biosystems

- Industry: Biotechnology
- Headquarters: Lausanne, Switzerland
- Website: www.adaptyvbio.com
- Total disclosed funding: $48M
- Latest round: Series A (Aug 25, 2026)
- Investors on record: 5

## About

Based in Switzerland, Adaptyv Biosystems develops a protein engineering platform using cell-free synthetic biology and nanofluidics. Based in Switzerland and founded in 2021, Adaptyv Biosystems Sàrl operates as a Biopole-based company. Daniel Nakhaee-Zadeh Gutierrez, Amir Shahein, Moustafa Houmani, and Julian Englert are the co-founders of the company. In August 2026, Adaptyv Biosystems Inc. raised USD 40 million series A funding led by new investor Highland Europe, with participation from returning investors Ace Ventures, byFounders and Y Combinator.
The company develops a protein engineering platform that uses automated nanofluidic platforms and cell-free systems. Rather than depending on genetically modified live cells to manufacture the desired protein, cell-free systems rely solely on biochemical components to convert a DNA sequence into a protein. Cell-free systems can be downsized and automated by avoiding the handling of living cells, making them a fit for high-throughput procedures that screen thousands of protein variations at once.

## Funding rounds

- Series A, Aug 25, 2026, $40M — Y Combinator, Highland Europe, byFounders, ACE Ventures
- Seed, Feb 1, 2025, $8M — byFounders, ACE Ventures, Founderful

## Investors

- byFounders (https://capitalatlas.ai/funds/byfounders) — Seed, Series A
- ACE Ventures — Seed, Series A
- Founderful (https://capitalatlas.ai/funds/founderful) — Seed
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Series A
- Highland Europe (https://capitalatlas.ai/funds/highland-europe) — Series A